Q1 EPS Estimate for Amicus Therapeutics Increased by Analyst

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Investment analysts at Zacks Research boosted their Q1 2027 earnings per share estimates for Amicus Therapeutics in a research report issued to clients and investors on Wednesday, July 9th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings per share of $0.08 for the quarter, up from their prior forecast of $0.07. The consensus estimate for Amicus Therapeutics' current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics' FY2027 earnings at $0.47 EPS.

A number of other research firms have also recently commented on FOLD. UBS Group lifted their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Wall Street Zen cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Finally, The Goldman Sachs Group lowered their price target on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Stock Down 3.3%

Amicus Therapeutics stock traded down $0.21 during midday trading on Thursday, reaching $6.09. The company's stock had a trading volume of 2,557,717 shares, compared to its average volume of 3,232,018. Amicus Therapeutics has a fifty-two week low of $5.51 and a fifty-two week high of $12.65. The company has a quick ratio of 2.47, a current ratio of 3.34 and a debt-to-equity ratio of 2.02. The company has a market cap of $1.88 billion, a P/E ratio of -67.66 and a beta of 0.51. The business has a 50-day simple moving average of $6.07 and a 200-day simple moving average of $7.79.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of FOLD. Wellington Management Group LLP raised its position in shares of Amicus Therapeutics by 18.8% during the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock worth $268,112,000 after purchasing an additional 4,497,950 shares during the last quarter. Nuveen LLC acquired a new position in Amicus Therapeutics in the 1st quarter valued at $28,741,000. Vestal Point Capital LP acquired a new position in Amicus Therapeutics in the 4th quarter valued at $31,557,000. Norges Bank acquired a new position in Amicus Therapeutics in the 4th quarter valued at $29,033,000. Finally, Assenagon Asset Management S.A. grew its stake in shares of Amicus Therapeutics by 641.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,533,854 shares of the biopharmaceutical company's stock valued at $20,249,000 after buying an additional 3,057,072 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.